	GSZD+MTX		мтх		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 MTX 7.5 mg/w							
Ji 2015	80	83	67	83	20.7%	1.19 [1.07, 1.34]	
Li and Guan 2018	43	45	35	45	9.3%	1.23 [1.04, 1.45]	
Li et al. 2019	38	40	24	39	4.0%	1.54 [1.19, 2.00]	
Xiao 2012	17	18	12	18	2.2%	1.42 [1.00, 2.00]	
Yuan 2018	42	44	33	44	7.9%	1.27 [1.06, 1.53]	
Zhou and Liu 2007	32	36	21	33	3.3%	1.40 [1.05, 1.85]	
Subtotal (95% CI)		266		262	47.4%	1.26 [1.17, 1.36]	•
Total events	252		192				
Heterogeneity: Tau ² =	0.00; Chi2	= 4.69	9, df = 5	(P = 0.	45); I ² =	0%	
Test for overall effect:	Z = 6.15 (P < 0.0	0001)				
1.1.2 MTX 10 mg/w							
Cui 2019	50	53	43	53	12.5%	1.16 [1.01, 1.35]	
Dong et al. 2020	29	30	24	30	7.3%	1.21 [1.00, 1.46]	
Huang et al. 2013	33	36	18	27	3.3%	1.38 [1.03, 1.83]	
Liang and Yang 2013	38	40	30	38	8.3%	1.20 [1.01, 1.44]	
Wu 2014	33	33	25	30	9.3%	1.20 [1.01, 1.42]	
Yu and Zhang 2010	36	40	29	41	5.3%	1.27 [1.02, 1.59]	
Zhang et al. 2019	41	45	33	45	6.7%	1.24 [1.02, 1.52]	
Subtotal (95% CI)		277		264	52.6%	1.22 [1.13, 1.30]	•
Total events	260		202				
Heterogeneity: Tau ² =	0.00; Chi ²	= 1.4	1, df = 6	(P = 0.	96); $I^2 = 1$	0%	
Test for overall effect:	Z = 5.39 (P < 0.0	00001)				
Total (95% CI)		543		526	100.0%	1.24 [1.18, 1.30]	● ●
Total events	512		394				
Heterogeneity: Tau ² =	0.00; Chi ²	= 6.64	4, df = 1	2 (P = 0).88); I ² =	- 0%	0.7 0.85 1 1.2 1.5
Test for overall effect:	Z = 8.14 (P < 0.0	0001)				0.7 0.85 1 1.2 1.5 Favors MTX Favors GSZD+MTX
Test for subgroup diff		1.12 0	FC JC	1 / D	0 45 12	00/	FAVOIS MILA FAVOIS GSZD+MILA

- 2 Supplementary Figure 1 Forest plot indicating the adjuvant therapy of GSZD
- 3 was independent of the dose of MTX. GuiZhi-ShaoYao-ZhiMu decoction; MTX:
- 4 methotrexate; M-H: Mantel-Haenszel; CI: confidence interval.

1

	GSZD+M		МТХ	-		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight M	-H, Random, 95% Cl	M-H, Random, 95% Cl
10.3.1 MTX							
Dong et al. 2020	29	30	24	30	7.3%	1.21 [1.00, 1.46]	
Yuan 2018	42	44	33	44	7.9%	1.27 [1.06, 1.53]	
Zhang et al. 2019	41	45	33	45	6.7%	1.24 [1.02, 1.52]	
Zhou and Liu 2007	32	36	21	33	3.3%	1.40 [1.05, 1.85]	
Subtotal (95% CI)		155		152	25.2%	1.26 [1.14, 1.40]	-
Total events	144		111				
Heterogeneity: Tau ² =				(P=0.	86); $I^2 = 0\%$		
Test for overall effect:	Z = 4.44 (P < 0.0	0001)				
10.3.2 MTX+NSAIDs							
Cui 2019	50	53	43	53	12.5%	1.16 [1.01, 1.35]	
li 2015	80	83	67	83	20.7%	1.19 [1.07, 1.34]	
Li et al. 2019	38	85 40	24	85 39	4.0%	1.54 [1.19, 2.00]	
Xiao 2012	17	18	12	18	4.0%	1.42 [1.00, 2.00]	
Subtotal (95% CI)	1/	194	12	193	39.3%	1.42 [1.00, 2.00] 1.25 [1.11, 1.41]	
Total events	185		146		55.570	(, ,	-
Heterogeneity: Tau ² =		= 4.89		$(\mathbf{P} = 0)$	$(18) \cdot 1^2 = 309$	6	
Test for overall effect:				(, = 0.	10,, 1 - 39/	•	
reserver overall enreet.	2 5	. 0.0	002)				
10.3.3 MTX+DMARDs							
Li and Guan 2018	43	45	35	45	9.3%	1.23 [1.04, 1.45]	
Yu and Zhang 2010	36	40	29	41	5.3%	1.27 [1.02, 1.59]	
Subtotal (95% CI)		85		86	14.7%	1.24 [1.09, 1.42]	
Total events	79		64				
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.06	, df = 1	(P = 0.	80); $I^2 = 0\%$		
Test for overall effect:	Z = 3.19 (P = 0.0	01)				
10.3.4 MTX+NSAIDs+							
Huang et al. 2013	33	36	18	27	3.3%	1.38 [1.03, 1.83]	
Liang and Yang 2013	38	50 40	30	38	5.5% 8.3%	1.20 [1.01, 1.44]	
Subtotal (95% CI)	20	76	50	65	0.5% 11.5%	1.25 [1.07, 1.45]	
Total events	71	70	40	05	11.3%	1.25 [1.07, 1.45]	
Heterogeneity: Tau ² =	71	0.66	48	(R 0	42) 12 00/		
Test for overall effect:				(P = 0.)	42), 1 = 0%		
rest for overall effect.	Z = 2.69 (P = 0.0	04)				
10.3.5 MTX+DMARDs	+glucoco	rticoid	drugs				
Wu 2014	33	33	25	30	9.3%	1.20 [1.01, 1.42]	
Subtotal (95% CI)		33		30	9.3%	1.20 [1.01, 1.42]	
Total events	33		25				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 2.10 (P = 0.0	4)				
		543		526	100.0%	1.24 [1.18, 1.30]	•
Total (95% CI)			394			·	•
	512						
Total events	512 0.00: Chi ²	= 6.64		P = 0	$(.88): ^2 = 0$		
	0.00; Chi ²		, df = 12	2 (P = 0	$(1.88); I^2 = 0$	6	0.7 0.85 1 1.2 1.5 Favors MTX Favors GSZD+MTX

2 Supplementary Figure 2. Subgroup meta-analysis indicating the adjuvant

3 therapy of GSZD was independent of the combined utilization of other drugs.

4 GSZD: GuiZhi-ShaoYao-ZhiMu decoction; MTX: methotrexate; M-H: Mantel-

5 Haenszel; CI: confidence interval.

1